Daclizumab
- Generic Name
- Daclizumab
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
- First Posted Date
- 2002-12-18
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 6
- Registration Number
- NCT00050661
- Locations
- 🇺🇸
Rockefeller University, New York, New York, United States
🇺🇸Rockefeller University Hospital, New York, New York, United States
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2002-12-18
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 20
- Registration Number
- NCT00050648
- Locations
- 🇺🇸
Rockefeller University Hospital, New York, New York, United States
🇺🇸Rockefeller University, New York, New York, United States
Daclizumab to Treat Chronic Immune Thrombocytopenia
- Conditions
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 24
- Registration Number
- NCT00049725
- Locations
- 🇺🇸
Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 434
- Registration Number
- NCT00048165
Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
- Conditions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 15
- Registration Number
- NCT00043667
- Locations
- 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States
Daclizumab to Treat Wegener's Granulomatosis
- Conditions
- First Posted Date
- 2002-06-24
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 75
- Registration Number
- NCT00040248
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Study of Daclizumab in Patients With Chronic, Persistent Asthma
- Conditions
- First Posted Date
- 2001-12-20
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 120
- Registration Number
- NCT00028288
- Locations
- 🇺🇸
Medical Research Associates, Long Beach, California, United States
🇺🇸Southern California Research, Mission Viejo, California, United States
🇺🇸Institute of Health Care Assessment, Inc., San Diego, California, United States
Islet Transplantation for Type 1 Diabetes
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2017-03-15
- Target Recruit Count
- 36
- Registration Number
- NCT00014911
- Locations
- 🇩🇪
Justus-Leibig University, Giessen, Germany
🇨🇦University of Alberta, Edmonton, Alberta, Canada
🇨🇭University of Geneva, Geneva, Switzerland
Pediatric Kidney Transplant Without Calcineurin Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-10-21
- Target Recruit Count
- 35
- Registration Number
- NCT00023231
- Locations
- 🇺🇸
Lauren Schenker, Rockville, Maryland, United States
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
- Conditions
- Interventions
- First Posted Date
- 2000-01-19
- Last Posted Date
- 2021-07-09
- Target Recruit Count
- 100
- Registration Number
- NCT00001962
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.